Navigation Links
Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
Date:2/9/2011

GENEVA, Feb. 9, 2011 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company specializing in the rapid development and engineering of high yield and stable mammalian cell-lines for therapeutic protein manufacturing, announced today a major expansion of the company's Swiss-based laboratories and staff.  The additional space comes in response to the increasing global demand for recombinant therapeutic proteins as well as outsourcing support for the rapid production of recombinant proteins.

Selexis' Swiss-based facilities now total over 13,000 square feet, a 100% increase over the former space.  This is the second major expansion for the company that originally opened in 2001 as a spin-off from the University of Lausanne.  The additional space houses larger laboratory and production functions, including a protein purification unit for small batches of purified research/pre-clinical proteins.  The Company will also increase the R&D and sales staff by more than 30%. The additional facilities and staff will enable Selexis to effectively service current and future client demands, while providing needed capacity to further expand its leading Selexis SURE™ Technology Platform and services.

"Our expansion was prompted by the global demand for outsourcing cell line engineering, the manufacturing of recombinant protein for pre-clinical research and interest in biosimilars as well as emerging technologies such as protein scaffolds. This investment will enable Selexis to provide even greater value to our current and future customers," said Dr. Igor Fisch, CEO, Selexis SA. "Our new laboratory space and staff represents a significant expansion for our business."

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins.  The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis VS™ Variant Screening and the proprietary Selexis CHO-M cell line.

For more information, visit http://www.selexis.com Media Contact:Robert Meister, Head of Marketing CommunicationsSelexis SA+1-602-953-1716robert.meister@selexis.com http://www.selexis.com
'/>"/>

SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. US Neuropathic Pain Market Value Doubles to $5 Billion by 2018
4. SleepQuest Compliance Again Doubles Industry Average
5. Carbon nanotube avalanche process nearly doubles current
6. Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production
7. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. RainDance Technologies Appoints Olex Vice President, System Development
10. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
11. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... (such as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs ... Insulin Assay from Salimetrics’ SalivaLab , the relationship between insulin and other ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:2/1/2017)... -- IDTechEx Research, a leading provider of independent market ... of a new report, Sensors for Robotics: Technologies, Markets and ... ... ... Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
Breaking Biology News(10 mins):